Published in Ann Intern Med on February 16, 2010
Pediatric severe asthma is characterized by eosinophilia and remodeling without T(H)2 cytokines. J Allergy Clin Immunol (2012) 1.45
Interleukin-4 production by follicular helper T cells requires the conserved Il4 enhancer hypersensitivity site V. Immunity (2012) 1.19
Retracted Gastrin-releasing peptide blockade as a broad-spectrum anti-inflammatory therapy for asthma. Proc Natl Acad Sci U S A (2011) 0.91
B-lymphocyte lineage cells and the respiratory system. J Allergy Clin Immunol (2013) 0.89
Emerging therapies for severe asthma. BMC Med (2011) 0.89
CD4+ T helper 2 cells--microbial triggers, differentiation requirements and effector functions. Immunology (2011) 0.86
Monoclonal Anti-TNF-α Antibodies for Severe Steroid-Dependent Asthma: A Case Series. Open Respir Med J (2013) 0.86
How variability in clinical phenotypes should guide research into disease mechanisms in asthma. Ann Am Thorac Soc (2013) 0.86
Application of genetic/genomic approaches to allergic disorders. J Allergy Clin Immunol (2010) 0.86
The critical role of complement alternative pathway regulator factor H in allergen-induced airway hyperresponsiveness and inflammation. J Immunol (2011) 0.85
Immunomodulation Mechanism of Antidepressants: Interactions between Serotonin/Norepinephrine Balance and Th1/Th2 Balance. Curr Neuropharmacol (2012) 0.83
Burn wound γδ T-cells support a Th2 and Th17 immune response. J Burn Care Res (2014) 0.83
Statin use and asthma control in patients with severe asthma. BMJ Open (2013) 0.81
Increased cytokine/chemokines in serum from asthmatic and non-asthmatic patients with viral respiratory infection. Influenza Other Respir Viruses (2013) 0.81
Elevated levels of serum IL-5 are associated with an increased likelihood of major depressive disorder. BMC Psychiatry (2012) 0.80
The Immunomodulatory Effect of You-Gui-Wan on Dermatogoides-pteronyssinus-Induced Asthma. Evid Based Complement Alternat Med (2012) 0.80
The Chinese Herbal Medicine Formula Sheng-Fei-Yu-Chuan-Tang Suppresses Th2 Responses and Increases IFN γ in Dermatophagoides pteronyssinus Induced Chronic Asthmatic Mice. Evid Based Complement Alternat Med (2013) 0.79
Basophils as a primary inducer of the T helper type 2 immunity in ovalbumin-induced allergic airway inflammation. Immunology (2014) 0.79
Differentiating asthma phenotypes in young adults through polyclonal cytokine profiles. Ann Allergy Asthma Immunol (2014) 0.78
Indoor microbial communities: Influence on asthma severity in atopic and nonatopic children. J Allergy Clin Immunol (2016) 0.78
KB-Rank: efficient protein structure and functional annotation identification via text query. J Struct Funct Genomics (2012) 0.77
Transcriptional Profiling of Th2 Cells Identifies Pathogenic Features Associated with Asthma. J Immunol (2016) 0.75
Achieving symptom control in patients with moderate asthma. Clin Med Insights Circ Respir Pulm Med (2011) 0.75
Procalcitonin guidance for reduction of antibiotic use in patients hospitalized with severe acute exacerbations of asthma: a randomized controlled study with 12-month follow-up. Crit Care (2014) 0.75
Correlation analysis of gene polymorphisms and β-lactam allergy. J Zhejiang Univ Sci B (2015) 0.75
Histone deacetylation of memory T lymphocytes by You-Gui-Wan alleviates allergen-induced eosinophilic airway inflammation in asthma. Chin Med (2015) 0.75
Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol (1986) 35.41
Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med (2004) 8.39
Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med (2009) 8.36
Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. American Thoracic Society. Am J Respir Crit Care Med (2000) 8.09
T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med (2009) 7.11
CD4 T cells: fates, functions, and faults. Blood (2008) 7.03
Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. J Allergy Clin Immunol (2007) 6.33
Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med (2009) 5.90
Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med (2008) 5.80
Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet (2001) 5.25
Asthma: defining of the persistent adult phenotypes. Lancet (2006) 4.78
Asthma. N Engl J Med (2009) 4.73
Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med (2002) 4.67
Asthma genetics 2006: the long and winding road to gene discovery. Genes Immun (2006) 4.14
The cytokine network in asthma and chronic obstructive pulmonary disease. J Clin Invest (2008) 3.90
Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet (2007) 3.90
A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med (2007) 3.83
TH17 cells mediate steroid-resistant airway inflammation and airway hyperresponsiveness in mice. J Immunol (2008) 3.42
Lung function in adults with stable but severe asthma: air trapping and incomplete reversal of obstruction with bronchodilation. J Appl Physiol (1985) (2007) 2.83
Distinguishing severe asthma phenotypes: role of age at onset and eosinophilic inflammation. J Allergy Clin Immunol (2004) 2.80
The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J (2001) 2.77
A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. Am J Respir Crit Care Med (2009) 2.56
An immunoepidemiological approach to asthma: identification of in-vitro T-cell response patterns associated with different wheezing phenotypes in children. Lancet (2005) 2.39
Omalizumab for asthma. N Engl J Med (2006) 2.31
Extent, patterns, and burden of uncontrolled disease in severe or difficult-to-treat asthma. Allergy (2007) 2.14
Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy (2004) 1.84
Untangling the complex web of IL-4- and IL-13-mediated signaling pathways. Sci Signal (2008) 1.57
IL4R alpha mutations are associated with asthma exacerbations and mast cell/IgE expression. Am J Respir Crit Care Med (2006) 1.57
Eosinophils in asthma--closing the loop or opening the door? N Engl J Med (2009) 1.49
Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma. Chest (2004) 1.42
IL-13 induced increases in nitrite levels are primarily driven by increases in inducible nitric oxide synthase as compared with effects on arginases in human primary bronchial epithelial cells. Clin Exp Allergy (2008) 1.36
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. Ann Rheum Dis (2008) 1.31
Polymorphisms in the IL4, IL4RA, and FCERIB genes and asthma severity. J Allergy Clin Immunol (2000) 1.25
The demise of anti IL-5 for asthma, or not. Am J Respir Crit Care Med (2007) 1.24
Non-adherence to endocrine therapy for breast cancer. Ann Oncol (2006) 1.03
IgE expression pattern in lung: relation to systemic IgE and asthma phenotypes. J Allergy Clin Immunol (2007) 1.01
Revising the immunological theories of asthma and allergy. Lancet (2005) 0.85
Extent of uncontrolled disease and associated medical costs in severe asthma--a PHARMO study. Curr Med Res Opin (2008) 0.84
Adherence to asthma self-management plans with inhaled corticosteroid and oral prednisone: A descriptive analysis. Respirology (2002) 0.84
An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med (2009) 9.38
International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J (2013) 8.39
Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med (2009) 7.17
Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. J Allergy Clin Immunol (2007) 6.33
Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med (2014) 4.95
Meta-analysis of genome-wide association studies of asthma in ethnically diverse North American populations. Nat Genet (2011) 3.68
Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. J Allergy Clin Immunol (2011) 3.35
A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma. Am J Respir Crit Care Med (2010) 3.11
Lung function in adults with stable but severe asthma: air trapping and incomplete reversal of obstruction with bronchodilation. J Appl Physiol (1985) (2007) 2.83
Distinguishing severe asthma phenotypes: role of age at onset and eosinophilic inflammation. J Allergy Clin Immunol (2004) 2.80
Heterogeneity of severe asthma in childhood: confirmation by cluster analysis of children in the National Institutes of Health/National Heart, Lung, and Blood Institute Severe Asthma Research Program. J Allergy Clin Immunol (2010) 2.27
Epithelial eotaxin-2 and eotaxin-3 expression: relation to asthma severity, luminal eosinophilia and age at onset. Thorax (2012) 2.14
Severe asthma in adults: what are the important questions? J Allergy Clin Immunol (2007) 1.85
An association between L-arginine/asymmetric dimethyl arginine balance, obesity, and the age of asthma onset phenotype. Am J Respir Crit Care Med (2012) 1.85
Function and regulation of SPLUNC1 protein in Mycoplasma infection and allergic inflammation. J Immunol (2007) 1.85
Pulmonary function abnormalities in HIV-infected patients during the current antiretroviral therapy era. Am J Respir Crit Care Med (2010) 1.81
Asthma in older adults: observations from the epidemiology and natural history of asthma: outcomes and treatment regimens (TENOR) study. Ann Allergy Asthma Immunol (2006) 1.77
Severe asthma: lessons learned from the National Heart, Lung, and Blood Institute Severe Asthma Research Program. Am J Respir Crit Care Med (2011) 1.76
Correlation of systemic superoxide dismutase deficiency to airflow obstruction in asthma. Am J Respir Crit Care Med (2005) 1.72
Gene expression in relation to exhaled nitric oxide identifies novel asthma phenotypes with unique biomolecular pathways. Am J Respir Crit Care Med (2014) 1.69
Obesity and asthma: an association modified by age of asthma onset. J Allergy Clin Immunol (2011) 1.64
Mast cell phenotype, location, and activation in severe asthma. Data from the Severe Asthma Research Program. Am J Respir Crit Care Med (2010) 1.62
Importance of hedgehog interacting protein and other lung function genes in asthma. J Allergy Clin Immunol (2011) 1.58
Transforming growth factor-beta2 induces bronchial epithelial mucin expression in asthma. Am J Pathol (2004) 1.58
Interleukin-15 inhibits spontaneous apoptosis in human eosinophils via autocrine production of granulocyte macrophage-colony stimulating factor and nuclear factor-kappaB activation. Am J Respir Cell Mol Biol (2002) 1.57
Eosinophils in asthma--closing the loop or opening the door? N Engl J Med (2009) 1.49
Recent asthma exacerbations: a key predictor of future exacerbations. Respir Med (2006) 1.49
Risk factors associated with persistent airflow limitation in severe or difficult-to-treat asthma: insights from the TENOR study. Chest (2007) 1.47
Predicting future risk of asthma exacerbations using individual conditional probabilities. J Allergy Clin Immunol (2011) 1.46
Airway lipoxin A4 generation and lipoxin A4 receptor expression are decreased in severe asthma. Am J Respir Crit Care Med (2008) 1.45
Severity assessment in asthma: An evolving concept. J Allergy Clin Immunol (2005) 1.42
Associations between fluctuations in lung function and asthma control in two populations with differing asthma severity. Thorax (2011) 1.39
Consistently very poorly controlled asthma, as defined by the impairment domain of the Expert Panel Report 3 guidelines, increases risk for future severe asthma exacerbations in The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study. J Allergy Clin Immunol (2009) 1.38
Early infection with respiratory syncytial virus impairs regulatory T cell function and increases susceptibility to allergic asthma. Nat Med (2012) 1.33
Defective apoptotic cell phagocytosis attenuates prostaglandin E2 and 15-hydroxyeicosatetraenoic acid in severe asthma alveolar macrophages. Am J Respir Crit Care Med (2005) 1.27
Predicting intermediate phenotypes in asthma using bronchoalveolar lavage-derived cytokines. Clin Transl Sci (2010) 1.25
15-Lipoxygenase 1 interacts with phosphatidylethanolamine-binding protein to regulate MAPK signaling in human airway epithelial cells. Proc Natl Acad Sci U S A (2011) 1.23
Registration-based assessment of regional lung function via volumetric CT images of normal subjects vs. severe asthmatics. J Appl Physiol (1985) (2013) 1.22
Selective downregulation of prostaglandin E2-related pathways by the Th2 cytokine IL-13. J Allergy Clin Immunol (2006) 1.21
Neutrophil-derived matrix metalloproteinase-9 is increased in severe asthma and poorly inhibited by glucocorticoids. J Allergy Clin Immunol (2003) 1.19
Exhaled nitric oxide identifies the persistent eosinophilic phenotype in severe refractory asthma. J Allergy Clin Immunol (2005) 1.16
Genome-wide association study identifies TH1 pathway genes associated with lung function in asthmatic patients. J Allergy Clin Immunol (2013) 1.15
Key findings and clinical implications from The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study. J Allergy Clin Immunol (2012) 1.14
Asthma diagnosis and airway bronchodilator response in HIV-infected patients. J Allergy Clin Immunol (2011) 1.13
Genome-wide association studies of asthma indicate opposite immunopathogenesis direction from autoimmune diseases. J Allergy Clin Immunol (2012) 1.11
Gender differences in IgE-mediated allergic asthma in the epidemiology and natural history of asthma: Outcomes and Treatment Regimens (TENOR) study. J Asthma (2006) 1.10
Regional fibroblast heterogeneity in the lung: implications for remodeling. Am J Respir Crit Care Med (2006) 1.10
IL-4 receptor α polymorphisms are predictors of a pharmacogenetic response to a novel IL-4/IL-13 antagonist. J Allergy Clin Immunol (2010) 1.06
Interleukin-13-induced MUC5AC is regulated by 15-lipoxygenase 1 pathway in human bronchial epithelial cells. Am J Respir Crit Care Med (2009) 1.05
The role of cytokines in chronic rhinosinusitis with nasal polyps. Curr Opin Otolaryngol Head Neck Surg (2008) 1.04
Prostaglandin D₂ pathway upregulation: relation to asthma severity, control, and TH2 inflammation. J Allergy Clin Immunol (2013) 1.04
IgE expression pattern in lung: relation to systemic IgE and asthma phenotypes. J Allergy Clin Immunol (2007) 1.01
Assessment of asthma control and asthma exacerbations in the epidemiology and natural history of asthma: outcomes and treatment regimens (TENOR) observational cohort. Curr Respir Care Rep (2012) 1.01
The IL6R variation Asp(358)Ala is a potential modifier of lung function in subjects with asthma. J Allergy Clin Immunol (2012) 0.98
Use of the Asthma Control Questionnaire to predict future risk of asthma exacerbation. J Allergy Clin Immunol (2010) 0.97
IL-4 receptor polymorphisms predict reduction in asthma exacerbations during response to an anti-IL-4 receptor α antagonist. J Allergy Clin Immunol (2012) 0.96
Safety of investigative bronchoscopy in the Severe Asthma Research Program. J Allergy Clin Immunol (2011) 0.95
Genome-wide ancestry association testing identifies a common European variant on 6q14.1 as a risk factor for asthma in African American subjects. J Allergy Clin Immunol (2012) 0.95
Sleep quality and asthma control and quality of life in non-severe and severe asthma. Sleep Breath (2011) 0.94
Interleukin-13 augments transforming growth factor-beta1-induced tissue inhibitor of metalloproteinase-1 expression in primary human airway fibroblasts. Am J Physiol Cell Physiol (2004) 0.93
Genomic differences distinguish the myofibroblast phenotype of distal lung fibroblasts from airway fibroblasts. Am J Respir Cell Mol Biol (2011) 0.93
Pathobiology of severe asthma. Annu Rev Pathol (2014) 0.91
Allergen-dependent solubilization of IL-13 receptor alpha2 reveals a novel mechanism to regulate allergy. J Allergy Clin Immunol (2006) 0.91
Current concepts of severe asthma. J Clin Invest (2016) 0.91
Phenotypes in asthma: useful guides for therapy, distinct biological processes, or both? Am J Respir Crit Care Med (2004) 0.91
Characteristics of perimenstrual asthma and its relation to asthma severity and control: data from the Severe Asthma Research Program. Chest (2013) 0.89
Human neutrophil elastase degrades SPLUNC1 and impairs airway epithelial defense against bacteria. PLoS One (2013) 0.88
Subtle immunodeficiency in severe asthma: IgA and IgG2 correlate with lung function and symptoms. Int Arch Allergy Immunol (2006) 0.88
Dupilumab in persistent asthma. N Engl J Med (2013) 0.88
MAPK regulation of IL-4/IL-13 receptors contributes to the synergistic increase in CCL11/eotaxin-1 in response to TGF-β1 and IL-13 in human airway fibroblasts. J Immunol (2012) 0.87
Safety and efficacy of the prostaglandin D2 receptor antagonist AMG 853 in asthmatic patients. J Allergy Clin Immunol (2012) 0.87
Mechanisms of tissue inhibitor of metalloproteinase 1 augmentation by IL-13 on TGF-beta 1-stimulated primary human fibroblasts. J Allergy Clin Immunol (2007) 0.85
Enhanced suppressive function of regulatory T cells from patients with immune-mediated diseases following successful ex vivo expansion. Clin Immunol (2010) 0.85
Role of insulin-like growth factor binding protein-3 in allergic airway remodeling. Am J Respir Crit Care Med (2009) 0.84
Tissue and BAL based biomarkers in asthma. Immunol Allergy Clin North Am (2007) 0.84
A profile of U.S. asthma centers, 2006. Ann Allergy Asthma Immunol (2007) 0.83
Airway eicosanoids in acute severe respiratory syncytial virus bronchiolitis. J Pediatr (2004) 0.83
A global perspective in asthma: from phenotype to endotype. Chin Med J (Engl) (2013) 0.82
The C11orf30-LRRC32 region is associated with total serum IgE levels in asthmatic patients. J Allergy Clin Immunol (2011) 0.81
Mast cells, their subtypes, and relation to asthma phenotypes. Ann Am Thorac Soc (2013) 0.81
Allergic rhinitis, asthma, airway biology, and chronic obstructive pulmonary disease in AJRCCM in 2004. Am J Respir Crit Care Med (2005) 0.78
Biologic therapy in asthma: entering the new age of personalized medicine. J Asthma (2014) 0.78
Type V collagen-induced tolerance prevents airway hyperresponsiveness. Am J Respir Crit Care Med (2013) 0.76
Asthma phenotypes in adults and clinical implications. Expert Rev Respir Med (2009) 0.76
Immune response modifiers in the treatment of asthma: A PRACTALL document of the American Academy of Allergy, Asthma & Immunology and the European Academy of Allergy and Clinical Immunology. J Allergy Clin Immunol (2012) 0.76
Severe asthma. Ann Am Thorac Soc (2014) 0.76
IRF5 distinguishes severe asthma in humans and drives Th1 phenotype and airway hyperreactivity in mice. JCI Insight (2017) 0.76
Characterization of autopsy-proven fatal asthma patients in São Paulo, Brazil. Rev Panam Salud Publica (2008) 0.75
Ensuring quality in pharmaceutical studies. Am J Respir Crit Care Med (2003) 0.75
Myofibroblast or smooth muscle: do in vitro systems adequately replicate tissue smooth muscle? Am J Respir Crit Care Med (2006) 0.75
Tiotropium for severe asthma: a step forward or more of the same? Pol Arch Med Wewn (2012) 0.75